Delivery Order SPE2DB20D1004-SPE2DB25FNKER
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens, valued at $1,862.88. This firm fixed-price delivery order, which concludes on July 24, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical supply delivery. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,725.61 to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ml insulin pens on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,734.26 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), carries a firm fixed price structure and is scheduled for completion by August 15, 2025. The product will be delivered to the company's facilities in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency (DLA) awarded a $2,289.58 delivery order to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ML insulin pens on July 22, 2025, with completion expected by July 23, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement under DLA's Medical Supply Chain operations. The award was issued to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters and serves as a...
- The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order valued at $2,108.70 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, using firm fixed-price terms with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed this delivery from its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a $2,289.71 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNKERDelivery Order
The Defense Logistics Agency awarded a $2,397 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens, with completion scheduled for August 19, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's existing $999,999,999 indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills diverse medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this flexible contract vehicle. The NovoLog insulin products fall within the company's extensive portfolio of specialty medications and diabetes treatments supplied to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/18/25 |